AbbVie Stock Prediction 2025, Best or Good?
Argus has set a new price target of $220 by the end of the current year. This target is driven by the strong sales growth of its product ‘Skyrizi, and ‘Ronivoq’. These 2 have replaced ‘Humira’ as key growth drivers.